Kyu-Il Lee¹ , Yu-Kyeong Yun² , Seung-Kyu Han^2,3 , Kyung-Chul Moon^2,3 , Sik Namgoong^2,3 ,

Seong-Ho Jeong³ , Eun-Sang Dhong³

¹Department of Plastic Surgery, Taean Public Health Office, Taean, Korea

²Diabetic Wound Center and Department of Plastic Surgery, Korea University Guro Hospital, Seoul, Korea

³Department of Plastic Surgery, Korea University College of Medicine, Seoul, Korea

Abstract

Background: Adequate tissue oxygenation is a key determinant of diabetic foot ulcer (DFU) outcomes. Though transcutaneous oxygen pressure (TcPO₂) is the gold standard for evaluating tissue oxygenation, its limited availability restricts routine clinical use. Consequently, toe pressure is frequently utilized as a practical surrogate; however, the direct correlation between these two modalities has yet to be rigorously investigated. This study aimed to assess the correlation and agreement between TcPO₂and toe pressure in patients with DFUs.

Methods: A retrospective review was conducted on 837 DFU patients who received simultaneous TcPO²and toe pressure assessments.

The correlation between the two tests was analyzed using the Pearson correlation coefficient, and agreement was evaluated using Bland– Altman analysis. To aid interpretation, a scatterplot and Bland–Altman plot were generated.

Results: TcPO₂and toe pressure demonstrated a strong correlation (R=0.66; 95% confidence interval, 0.62 to 0.70; P<0.001). Bland–

Altman analysis showed a mean bias of 26.9 mmHg (standard deviation of differences, 28.8 mmHg; 95% limits of agreement, −28.9 to 82.6 mmHg) between toe pressure and TcPO₂, reflecting limited agreement and increased variability at higher perfusion levels.

Conclusion: TcPO₂and toe pressure are strongly correlated. However, they are not interchangeable, particularly in DFU patients with high tissue perfusion.

Keywords: Diabetic foot; Foot ulcer; Ischemia; Microcirculation

本文转载于J Clin Aesthet Dermatol. 2018;11(11):36–39，不代表本网站赞同其观点和对其真实性负责，我们只作于阅读分享，非商业用途，如若侵权，请告知删除。​

Ewa A. BURIAN¹, Lubna SABAH¹, Klaus KIRKETERP-MØLLER¹, Glenn GUNDERSEN² and Magnus S. ÅGREN^1,3,4

¹Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark,
²SoftOx Solutions AS, Oslo, Norway, ³Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, and ⁴Department of Clinical
Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Yuta Tsujisaka,^1,2,5 Takeshi Hatani,^1,2,5 Chikako Okubo,¹ Ryo Ito,¹ Azuma Kimura,¹ Megumi Narita,¹

Kazuhisa Chonabayashi,^1,3 Shunsuke Funakoshi,^1,4 Antonio Lucena-Cacace,¹ Taro Toyoda,1 Kenji Osafune,¹

Takeshi Kimura,² Hirohide Saito,^{1, *} and Yoshinori Yoshida^{1,4, *}

¹Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan

²Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan

³Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan

⁴Takeda-CiRA Joint Program (T-CiRA), Fujisawa 251-0012, Japan

⁵These authors contributed equally

*Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (H.S.), 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (Y.Y.)

https://doi.org/10.1016/j.stemcr.2022.05.003

SUMMARY
For regenerative cell therapies using pluripotent stem cell (PSC)-derived cells, large quantities of purified cells are required. Magnetic-activated cell sorting (MACS) is a powerful approach to collect target antigen-positive cells; however, it remains a challenge to purify various cell types efficiently at large scale without using antibodies specific to the desired cell type. Here we develop a technology that combines microRNA (miRNA)-responsive mRNA switch (miR-switch) with MACS (miR-switch-MACS) to purify large amounts of PSC-derived cells rapidly and effectively. We designed miR-switches that detect specific miRNAs expressed in target cells and controlled the translation of a CD4-coding transgene as a selection marker for MACS. For the large-scale purification of induced PSC-derived cardiomyocytes (iPSC-CMs), we transferred miR-208a-CD4 switch-MACS and obtained purified iPSC-CMs efficiently. Moreover, miR-375-CD4 switch-MACS highly purified pancreatic insulin-producing cells and their progenitors expressing Chromogranin A. Overall, the miR-switch-MACS method can efficiently purify target PSC-derived cells for cell replacement therapy.